BACKGROUND: Recent data support the hypothesis that combining lapatinib and trastuzumab with taxane chemotherapy may offer added clinical benefit to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). This study examined the safety of the triplet combination in first-line HER2-positive MBC. PATIENTS AND METHODS: Patients were enrolled into three sequential cohorts; the last two cohorts were added by protocol amendment following review of safety data from cohort 1. Patients in cohort 1 received lapatinib (1000 mg/day) plus paclitaxel (80 mg/m(2) per week, 3 of every 4 weeks); cohort 2 received lapatinib (1000 mg/day) plus paclitaxel (70 mg/m(2) per week, 3 of every 4 weeks); and cohort 3 received lapatinib (750 mg/day) plus paclitaxel (80 mg/m(2) per week, 3 of every 4 weeks). All received standard trastuzumab dosing. The primary objective was assessment of dose-limiting toxicities, safety, and tolerability of this combination. RESULTS: The most frequent adverse events (AEs) for all cohorts were diarrhea (89%), rash (79%), fatigue (73%), alopecia (63%), nausea (63%), and vomiting (40%). In cohorts 1 and 2, the incidence of grade 3 diarrhea was 62% and 50%, respectively; in cohort 3, the incidence was 25% (with prophylactic loperamide). Dehydration was the most frequent serious AE (10%). Across cohorts, overall response rate was 75%. CONCLUSIONS: The dose-limiting toxicity of paclitaxel, trastuzumab, and lapatinib in first-line HER2-positive MBC was diarrhea. Of the triplet combinations tested, the cohort receiving 750 mg/day dose of lapatinib had the lowest incidence of diarrhea; therefore, this dose should be used in further studies on the treatment of MBC.
BACKGROUND: Recent data support the hypothesis that combining lapatinib and trastuzumab with taxane chemotherapy may offer added clinical benefit to patients with humanepidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). This study examined the safety of the triplet combination in first-line HER2-positive MBC. PATIENTS AND METHODS: Patients were enrolled into three sequential cohorts; the last two cohorts were added by protocol amendment following review of safety data from cohort 1. Patients in cohort 1 received lapatinib (1000 mg/day) plus paclitaxel (80 mg/m(2) per week, 3 of every 4 weeks); cohort 2 received lapatinib (1000 mg/day) plus paclitaxel (70 mg/m(2) per week, 3 of every 4 weeks); and cohort 3 received lapatinib (750 mg/day) plus paclitaxel (80 mg/m(2) per week, 3 of every 4 weeks). All received standard trastuzumab dosing. The primary objective was assessment of dose-limiting toxicities, safety, and tolerability of this combination. RESULTS: The most frequent adverse events (AEs) for all cohorts were diarrhea (89%), rash (79%), fatigue (73%), alopecia (63%), nausea (63%), and vomiting (40%). In cohorts 1 and 2, the incidence of grade 3 diarrhea was 62% and 50%, respectively; in cohort 3, the incidence was 25% (with prophylactic loperamide). Dehydration was the most frequent serious AE (10%). Across cohorts, overall response rate was 75%. CONCLUSIONS: The dose-limiting toxicity of paclitaxel, trastuzumab, and lapatinib in first-line HER2-positive MBC was diarrhea. Of the triplet combinations tested, the cohort receiving 750 mg/day dose of lapatinib had the lowest incidence of diarrhea; therefore, this dose should be used in further studies on the treatment of MBC.
Entities:
Keywords:
Breast cancer; HER2; Lapatinib; Paclitaxel; Trastuzumab
Authors: Francisco J Esteva; Vicente Valero; Daniel Booser; Laura T Guerra; James L Murray; Lajos Pusztai; Massimo Cristofanilli; Banu Arun; Bita Esmaeli; Herbert A Fritsche; Nour Sneige; Terry L Smith; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2002-04-01 Impact factor: 44.544
Authors: D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich Journal: Science Date: 1989-05-12 Impact factor: 47.728
Authors: Giampietro Gasparini; Massimo Gion; Luigi Mariani; Paola Papaldo; Diana Crivellari; Gianfranco Filippelli; Alessandro Morabito; Vittorio Silingardi; Francesco Torino; Antonella Spada; Matelda Zancan; Livia De Sio; Antonio Caputo; Francesco Cognetti; Antonio Lambiase; Dino Amadori Journal: Breast Cancer Res Treat Date: 2006-07-19 Impact factor: 4.872
Authors: Gottfried E Konecny; Mark D Pegram; Natarajan Venkatesan; Richard Finn; Guorong Yang; Martina Rahmeh; Michael Untch; David W Rusnak; Glenn Spehar; Robert J Mullin; Barry R Keith; Tona M Gilmer; Mark Berger; Karl C Podratz; Dennis J Slamon Journal: Cancer Res Date: 2006-02-01 Impact factor: 12.701
Authors: Henry L Gomez; Dinesh C Doval; Miguel A Chavez; Peter C-S Ang; Zeba Aziz; Shona Nag; Christina Ng; Sandra X Franco; Louis W C Chow; Michael C Arbushites; Michelle A Casey; Mark S Berger; Steven H Stein; George W Sledge Journal: J Clin Oncol Date: 2008-05-05 Impact factor: 44.544
Authors: Bronwen J Mayo; Kate R Secombe; Anthony D Wignall; Emma Bateman; Daniel Thorpe; Claudio Pietra; Dorothy M Keefe; Joanne M Bowen Journal: Cancer Chemother Pharmacol Date: 2020-02-14 Impact factor: 3.333
Authors: Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey Journal: Oncotarget Date: 2014-07-15
Authors: Ricardo Fernandes; Sasha Mazzarello; Brian Hutton; Risa Shorr; Habeeb Majeed; Mohammed Fk Ibrahim; Carmel Jacobs; Michael Ong; Mark Clemons Journal: Support Care Cancer Date: 2016-05-05 Impact factor: 3.603
Authors: Neil M Iyengar; Monica N Fornier; Steven M Sugarman; Maria Theodoulou; Tiffany A Troso-Sandoval; Gabriella M D'Andrea; Pamela R Drullinsky; Devika Gajria; Shari B Goldfarb; Elizabeth A Comen; Diana E Lake; Shanu Modi; Tiffany A Traina; Mario E Lacouture; Melanie F Chen; Sujata Patil; José Baselga; Larry Norton; Clifford A Hudis; Chau T Dang Journal: Clin Breast Cancer Date: 2015-09-25 Impact factor: 3.225
Authors: Antonio Llombart-Cussac; Begoña Bermejo; Cristian Villanueva; Suzette Delaloge; Serafín Morales; Judith Balmaña; Kepa Amillano; Hervé Bonnefoi; Ana Casas; Luis Manso; Henri Roché; Santiago Gonzalez-Santiago; Joaquín Gavilá; Pedro Sánchez-Rovira; Serena Di Cosimo; Nadia Harbeck; Eric Charpentier; Ignacio Garcia-Ribas; Nina Radosevic-Robin; Claudia Aura; Jose Baselga Journal: Breast Cancer Res Treat Date: 2015-11-04 Impact factor: 4.872
Authors: Joanne Mortimer; Jae Jung; Yuan Yuan; Laura Kruper; Daphne Stewart; Samuel Chung; Kim Wai Yu; Mary Mendelsohn; Massimo D'Apuzzo; Bernard Tegtmeier; Sanjeet Dadwal Journal: Breast Cancer Res Treat Date: 2014-11-11 Impact factor: 4.872